Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M

MYOMO, INC.

2024-Q3 EPS reported -$0.16 revenue$20,482,742

Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.
Gross margin 75.4%, +670 bps; backlog record 316 units (+71%); 225 MyoPro orders (+44%).
Raised FY2024 revenue guidance to $30-31M from prior $28-30M; expects Q4 rev $9.5-10.5M.
Cash $7.0M; expects approaching operating cash flow breakeven in Q4.
Cost per pipeline add $1,618, down 25%; 1,263 patients in pipeline (+21%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.